Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients

Naya, Masanao; Tsukamoto, Takahiro; Morita, Koichi et al.

Journal of the American College of Cardiology, 2007, 50(12), 1144-1149

Permalink : https://hdl.handle.net/2115/30255

このアイテムのアクセス数:1,629件（2026-08-16 11:27 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
JACC50-12 pdf 290 KB 1,584

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/30255
タイトル
Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients
著者
Naya, Masanao ; Tsukamoto, Takahiro ; Morita, Koichi ; Katoh, Chietsugu ; Furumoto, Tomoo ; Fujii, Satoshi ; Tamaki, Nagara ; Tsutsui, Hiroyuki
著者名
Naya, Masanao
著者名
Tsukamoto, Takahiro
著者名
Morita, Koichi
著者名
Katoh, Chietsugu
著者名
Furumoto, Tomoo
著者名
Fujii, Satoshi
著者名
Tamaki, Nagara
e-Rad_Researcher
70264017
著者名
Tsutsui, Hiroyuki
言語
英語
キーワード
coronary endothelial function
olmesartan
amlodipine
hypertension
positron emission tomography
発行日
2007-09-18
出版者
Elsevier Inc.
収録物名
Journal of the American College of Cardiology
巻(号)
50(12)
ページ
1144-1149
抄録
Objectives: We aimed to compare the effects of angiotensin II receptor blocker (ARB) olmesartan versus calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension. Background: ARB is thought to have greater beneficial effects on coronary vasomotion via directly blocking action of angiotensin II than CCB. Methods: Twenty-sex patients with untreated essential hypertension were prospectively assigned to the treatment with either olmesartan (27.7±12.4 mg per day, n=13) or amlodipine (5.6±1.5 mg per day, n=13) for 12 weeks. Changes of corrected myocardial blood flow (ΔMBF) and coronary vascular resistance (ΔCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, hs-CRP, interleukin-6, tumor necrosis factor-α, and superoxide dismutase (SOD) were also measured. Results: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (−28.7±16.2 vs. −26.7±10.8 mmHg). In olmesartan group, ΔMBF tended to be greater (−0.15±0.19 vs. 0.03±0.17 ml/g/min, P=0.09 by 2-way ANOVA) and ΔCVR was significantly decreased (7.9±23.5 vs. −16.6±18.0 mmHg/[ml/g/min], P<0.05) after treatment whereas they did not change in amlodipine group (ΔMBF: −0.15±0.12 vs. −0.12±0.20 ml/g/min; ΔCVR: 6.5±18.2 vs. 4.8±23.4 mmHg/[ml/g/min]). Serum SOD activity tended to increase (4.74±4.77 vs. 5.57±4.74 U/ml, P=0.07 by 2-way ANOVA) only in olmesartan group. Conclusions: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independently of BP lowering. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
PISSN
0735-1097
関連情報
PMID
17868805
URI
http://content.onlinejacc.org/
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1016/j.jacc.2007.06.013